Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 3/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | PREP | P48147 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL889013 | 0.90 | GRIN2B (0.53) | GRIN2BPREPTSHRL3MBTL1KDM4E | |
| SCHEMBL34473807 | 0.81 | PREP (0.54) | GFERPREPMEN1KMT2ATSHR | |
| SCHEMBL22158059 | 0.81 | PREP (0.54) | GFERPREPMEN1KMT2ATSHR | |
| SCHEMBL13060873 | 0.81 | PREP (0.54) | GFERPREPMEN1KMT2ATSHR | |
| SCHEMBL5348471 | 0.81 | GRIN2B (0.80) | GRIN2B | |
| SCHEMBL15937048 | 0.79 | PREP (0.52) | GFERPREPKMT2ATSHRL3MBTL1 | |
| SCHEMBL13006645 | 0.79 | ACE2 (0.56) | GFERPREPMEN1KMT2ATSHR | |
| SCHEMBL10154291 | 0.78 | FKBP1A (0.54) | GFERPREPTSHRL3MBTL1KDM4E | |
| SCHEMBL13853680 | 0.78 | PREP (0.50) | GFERPREPKMT2ATSHRL3MBTL1 | |
| SCHEMBL14366007 | 0.78 | PREP (0.50) | GFERPREPKMT2ATSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | GRIN2B 4821/4885GFER 1965/4885PREP 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.